MabThera.com
skip to the content
Search
search
Home
About MabThera
Treating NHL
Additional supporting studies in NHL
About NHL
Haematology service
Medical education
Webcast
Sitemap
Tell a friend
Home
About MabThera
News
Active ingredient
Mechanism of action
MabThera MoA
Synergy with chemotherapy and radiotherapy
Product characteristics
Molecular features
CD20: an ideal target antigen
Clinical pharmacokinetics of MabThera
Approval information
Safety information
Treating NHL
Untreated follicular NHL
MabThera plus chemotherapy first-line
Administration
Relapsed/refractory follicular NHL
Standard monotherapy
Administration monotherapy
Maintenance Therapy
Administration Maintenance Therapy
Untreated DLBCL
First line CHOP
Administration CHOP
About NHL
Disease background
Possible factors that may contribute to NHL development
Presenting signs and symptoms of NHLs
Lymphoma diagnosis
Classification of NHL
NHL subtypes
Follicular lymphoma FL
Small lymphocytic lymphoma SLL
Marginal zone B-cell lymphoma MZL
Diffuse large B-cell lymphoma DLBCL
Burkitts lymphoma BL
B cell lymphoblastic lymphoma
Mantle cell lymphoma MCL
Lymphoblastic lymphoma LL
NK cell or g/d Tcell lymphomas
Prognostic factors in NHL
International Prognostic index IPI
Follicular Lymphoma International Prognostic Index FLIPI
Bcl-2 and β2-microglobulin as prognostic tools
Haematology service
Event Calendar
Login
You're logged out.
Login and registration